Key facts
- This page summarizes Peter Kolchinsky's Form 4 filing for Forma Therapeutics Holdings, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 21 Jun 2021, 19:01.
Peter Kolchinsky - 17 Jun 2021 Form 4 Insider Report for Forma Therapeutics Holdings, Inc.
- Reporting relationship
- Director, 10%+ Owner
- Issuer ticker
- N/A
- Reported as of
- 17 Jun 2021
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 21 Jun 2021, 19:01:53 UTC
- Next SEC filing
- 24 Jun 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeannette Potts, as Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Peter Kolchinsky filed Form 4 for Forma Therapeutics Holdings, Inc. on 21 Jun 2021.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
FMTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +2,750
- Change %
- Price
- $0.000000
- Shares after
- 2,750
- Date
- 17 Jun 2021
- Ownership
- Direct
- Footnotes
- F1, F2
FMTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 9,011,651
- Date
- 17 Jun 2021
- Ownership
- See footnote
- Footnotes
- F3, F4
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FMTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +8,375
- Change %
- Price
- $0.000000
- Shares after
- 8,375
- Date
- 17 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 8,375
- Exercise price
- $25.35
- Footnotes
- F2, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
These shares represent restricted stock units and will be settled into common stock upon vesting. Each restricted stock unit would be converted into one share of FMTX common stock.
Footnote F2
Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option and restricted share units for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon sale of the common stock underlying the option and restricted share units, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option, restricted share units and the underlying common stock.
Footnote F3
Includes (a) 7,500,226 shares held by the Fund and (b) 1,511,425 shares held by the Nexus Fund.
Footnote F4
The Adviser is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which the Reporting Person and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, the Reporting Person and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.
Footnote F5
This option shall vest and become exercisable in full upon the earlier to occur of (i) June 17, 2022 and (ii) the next annual meeting of the Issuer's stockholders.